JAZZ News and Press, Jazz Pharmaceuticals plc From 06/08/22

Top Ancillary Cannabis Stocks For June 2022 Are you looking for the best marijuana stocks to invest in for the long term? The best cannabis stocks to watch right now are recognized for having high market volatility, making it difficult for long-term investors to find stability. Long...

Jazz Pharmaceuticals missed first quarter revenue estimates, but management raised the full-year guidance. The launch of Xywav in idiopathic hypersomnia looks strong, and has driven the best quarter for the oxybate franchise since mid-2020. Business development activity picked up ...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported data from a phase 2/3 trial of a new dosing regimen of its therapy Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn). The results — which were presented at the American Society of Clinical Oncology (ASCO) meetin...

Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting PR Newswire Oral presentation confirms pati...

The Cannabis Sector And Top Marijuana Stocks In June Top marijuana stocks have started June with some momentum after reaching new lows in May. Many experts are calling this recent rise a bear market rally since the broader markets have regained some of their losses from last month. ...

Top Marijuana Stocks To Watch As New Month Of Trading Begins At the moment marijuana stocks are still in a volatile place. Over the last several weeks many cannabis stocks have quickly risen and fallen. Yet this is not all bad if you are able to play the short game better than o...

Jazz Pharmaceuticals to Participate in the Jefferies Healthcare Conference PR Newswire DUBLIN , June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference o...

Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine PR Newswire Seventeen abstracts debut new data across narcolepsy and idiopathic hypersomnia DUBLIN , June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals ...

A delay in approval of Avadel Pharmaceuticals (NASDAQ:AVDL) FT218 for daytime sleepiness and cataplexy is seen as a boon for rival Jazz Pharmaceuticals (NASDAQ:JAZZ). The delay, due to a REMS patent, is an "incremental positive" for Jazz Pharmaceuticals, said Goldman Sachs analyst Madhu Kumar...

Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis, Alzheimer’s, Parkinson’s, among others. Accordin...